The Potential Value of Near Patient Platelet Function Testing in PCI : Randomised Comparison of 600 mg versus 900 mg Clopidogrel Loading Doses

Abstract EN

Whilst poor response to clopidogrel is associated with adverse outcomes uncertainty exists as to how (a) response should be assessed and (b) poor responders managed.

We utilised VerifyNow P2Y12 and short Thrombelastography (TEG) to assess 900 mg doses in (i) initial poor responders to 600 mg and (ii) in a randomised comparison with 600 mg.

Blood was taken before and six hours post clopidogrel in (i) 30 volunteers receiving 600 mg (poor responders received 900 mg > two weeks later) and (ii) 60 patients randomized 1 : 1 to 600 mg or 900 mg doses.

Poor response was defined as TEG %Clotting Inhibition (%CIn) or VerifyNow Platelet Response Unit (PRU) reduction <30%.

(i) Poor responders to 600 mg had greater PRU reduction (45.0 versus 20.1%, P = 0.03) and greater %CIn (22.9 versus −15.1%, P = 0.01) after 900 mg but (ii) there were no significant differences between the patient groups.

Near-patient assessment of response to clopidogrel is feasible and clinically useful.

Whilst ineffective on a population basis 900 mg doses increase the effect of clopidogrel in initial poor responders.